Loading clinical trials...

Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients | Clinical Trials | Clareo Health

RECRUITINGPHASE2

Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients

A Multicenter, Randomized, Double-Blind, Crossover, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of BRIMOCHOL PF, CARBACHOL PF in Chinese Patients With Presbyopia

NCT06948357•Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

View on ClinicalTrials.gov

Summary

A multicenter, randomized, double-Blind, crossover, placebo-controlled Phase II clinical Study to evaluate the efficacy and safety of BRIMOCHOL PF and CARBACHOL PF in the treatment of Chinese patients with presbyopia.

Detailed Description

119 subjects were planned to be enrolled in this study and randomly assigned in equal proportions into 7 treatment sequences. Each subject will receive a total of 7 treatments, each treatment period will be 1 day, and two adjacent visits during the treatment period need to be eluted for at least 3 days。 The study period included the screening period (Day 14\~Day 1) with 1 visit and the treatment period (Day 0\~Day 30) with 7 visits. There were a total of 8 visits in this study, with a duration of 32 to 45 days.

Eligibility

Age

45 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. At Visit 1 (Screening Period), the age ranges from 45 to 75 years old, regardless of gender
•2. At Visit 1 (Screening Period), the corrected distance visual acuity of either eye is ≥ 0.8 (National Standard Logarithmic Visual Acuity Scale,decimal visual acuity) in the clinical routine manifest refraction (distance vision).
•3. At Visit 1 (Screening Period), the manifest refraction (distance vision under mesopic conditions) results are as follows: For any eye,-4.00D ≤ equivalent spherical lens power ≤ +2.00D, and the negative cylinder lens power is ≥-2.00D;
•4. At least one eye meeting the following at both Visit 1 and Visit 2:
•1. Under mesopic conditions, monocular corrected near visual acuity (MCNVA) ≤65 ETDRS letters (equivalent to decimal visual acuity 0.4) ;
•2. Under mesopic conditions, monocular corrected near visual acuity with a multiple-pinhole occluder (MCNVA\_P) improves by ≥15 ETDRS letters compared to monocular corrected near visual acuity without the occluder (MCNVA).
•5. During Visit 1 (Screening Period) and Visit 2, both eyes must meet the following criteria:under mesopic conditions, binocular corrected near visual acuity (BCNVA) is ≤65 ETDRS letters (equivalent to decimal visual acuity 0.4);
•6. Any eye is phakic or implanted with a monofocal intraocular lens (IOL);
•7. Normal iris and pupillary morphology in any eye, with normal light reflex and an interocular pupillary diameter difference ≤1 mm during screening;

Exclusion Criteria

•1. Use of corneal or scleral contact lenses within 28 days prior to screening or planned for the duration of the study;
•2. Narrow anterior chamber angle (Van Herick grade ≤2 via slit lamp examination) or previous iridotomy or resection in either eye；
•3. Ocular history in any eye: hyphema, ciliary body detachment, iridodonesis, or ocular trauma；
•4. Any eye with a corneal abnormality that, in the judgment of the investigator, affects visual acuity or intraocular pressure measurements, including moderate to severe dry eye (e.g., significant signs of ocular surface damage (≥5 corneal fluorescein staining spots) on slit lamp microscopy);
•5. Any phakic eye has a history of lens tremor, subluxation, or suspected zonular laxity; or any pseudophakic eye has undergone posterior capsulotomy or uses multifocal or extended depth of focus intraocular lenses.
•6. Any eye with an axial length of ≥26mm;
•7. Either eye has undergone intraocular or corneal surgery (only non-complicated cataract surgery with a monofocal lens placed in the capsular bag more than 6 months after the date of surgery is permitted; complicated cataract surgery is defined as surgery that has resulted in a rupture of the capsule or placement of an IOL outside the capsule (ciliary sulcus, scleral or iris fixation, anterior chamber, etc.));
•8. Either eye has a history of congenital or traumatic cataract, congenital aphakia, or opacities in the refractive media that affect visual acuity in the visual axis area.
•9. History of uveitis, low intraocular pressure (IOP \< 9 mmHg), glaucoma or hypertension (IOP \> 21 mmHg) or pseudoexfoliation syndrome in either eye;
•10. Active ocular or periocular infection or inflammation in either eye, or a history of recurrent infection or chronic infection (e.g., herpes virus infection) in either eye;
+2 more criteria

Locations (1)

Optometry Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Key Dates

Start Date

March 24, 2025

Primary Completion Date

September 30, 2025

Completion Date

December 30, 2025

Last Updated

April 29, 2025

Enrollment

119

ESTIMATED participants

Conditions

Presbyopia

Interventions

BRIMOCHOL PF eye drops; CARBACHOL PF eye drops; Brimonidine eye drops; Placebo

DRUG

Contacts

Peiqiu Gu

CONTACT

0577-88075582 EYE_ec@126.com

Xiaochen Wang

CONTACT

IC-8 Apthera IOL New Enrollment Post Approval Study

NCT06060041

CataractPresbyopia+1 more

View study

RECRUITINGNA

Clinical Applications of Advanced Ophthalmic Imaging

NCT03135327

Multiple SclerosisDry Eye Syndromes+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients

Inclusion Criteria

Exclusion Criteria

IC-8 Apthera IOL New Enrollment Post Approval Study

Clinical Applications of Advanced Ophthalmic Imaging

Head-to-Head Comparison of Five Enhanced Depth of Focus IOLs and One Monofocal IOL

A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add

Evaluation of Safety and Efficacy of Intrastromal Implantation of CorVision® Bioengineered Corneal Inlay for Correction of Presbyopia.

Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement